Success Stories

Latest Publications High content drug screening for Fanconi anemia therapeutics.

Montanuy, H. et al.
Orphanet J. Rare Dis. 15 1–9 (2020)

Background Fanconi anemia is a rare disease clinically characterized by malformations, bone marrow failure and an increased risk of solid tumors and hematologic malignancies. The only therapies available are hematopoietic stem cell transplantation for bone marrow failure or leukemia, and surgical resection for solid tumors. Therefore, there is still an urgent need for new therapeutic […]

Latest Publications Identification of repositionable drugs with novel antimycotic activity by screening the Prestwick Chemical Library against emerging invasive moulds.

Yousfi, H., Ranque, S., Cassagne, C., Rolain, J. M. & Bittar, F.
J. Glob. Antimicrob. Resist. 21 314–317 (2020)

Objectives: The incidence of severe filamentous fungal infections has increased over the past decade. Some of these filamentous fungi are resistant to available antifungals; it is thus urgent to find new compounds that are active against such life-threatening pathogens. Methods: In this study, 1280 drugs (Prestwick Chemical Library) were tested against six multidrug-resistant (MDR) filamentous fungi, includingAspergillus, […]

Latest Publications The first wide-scale drug repurposing screen using the Prestwick Chemical Library (1200 bioactive molecules) against Neisseria gonorrhoeae identifies high in vitro activity of auranofin and many additional drugs.

Foerster, S. et al.
Apmis 128 242–250 (2020)

Treatment options for gonorrhoea are scarce. Drug repurposing of bioactive molecules approved for other conditions might therefore be of value. We developed a method for wide-scale, systematic drug repurposing screen to identify molecules with activity against Neisseria gonorrhoeae and screened the Prestwick Chemical Library (1200 FDA-approved drugs). As a proof-of-concept, we further examined one promising […]

Latest Publications Identification of cardiac glycosides as novel inhibitors of eif4a1-mediated translation in triple-negative breast cancer cells.

Howard, C. M., Estrada, M., Terrero, D., Tiwari, A. K. & Raman, D.
Cancers (Basel) 12 1–18 (2020)

The eukaryotic translation initiation factor 4F complex (eIF4F) is a potential chemotherapeutic target in triple-negative breast cancer (TNBC). This complex regulates cap-dependent translational initiation and consists of three core proteins: eIF4E, eIF4G, and eIF4A1. In this study, we focus on repositioning compounds as novel inhibitors of eIF4A1-mediated translation. In order to accomplish this goal, a […]

Case studies Clinical validation of blood/brain glutamate grabbing in acute ischemic stroke.

A. da Silva-Candal, A. Pérez-Diaz, M. Santamaria, C. Correa-Paz, M. Rodriguez-Yanez, A. Arda, M. Perez-Mato, R. Iglesias-Rey, J. Brea, J. Azuaje, E. Sotelo, T. Sobrino, MI Loza, J. Castillo & F. Campos
Ann. Neurol. 84 260–273 (2018)

Blood/brain-glutamate grabbing is an emerging concept in the treatment of ischemic stroke, where essentially the deleterious effects of glutamate after ischemia are ameliorated by coaxing glutamate to enter the bloodstream and thus reducing its concentration in the brain. The authors aim to demonstrate the clinical efficacy of blood glutamate grabbers in patients with stroke, and […]

Case studies Antimicrobial and Antibiofilm Activity of Synergistic Combinations of a Commercially Available Small Compound Library With Colistin Against Pseudomonas aeruginosa.

Torres, N. S. et al.
Frontiers in Microbiology 9, 1–12

Abstract Biofilm-associated Pseudomonas aeruginosa infections remain a significant clinical challenge since the conventional antibiotic treatment or combination therapies are largely ineffective; and new approaches are needed. To circumvent the major challenges associated with discovery of new antimicrobials, we have screened a library of compounds that are commercially available and approved by the FDA (Prestwick Chemical […]